KODATEF (Biocelect Pty Ltd)
Product name
KODATEF
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
202 working days (255)
Active ingredients
tafenoquine succinate
Registration type
NCE/NBE
Indication
KODATEF (tablets) is an antimalarial indicated for the prevention of malaria in adults 18 years of age and above for up to 6 months of continuous dosing.